Tamgiblimab Biosimilar - Research Grade

Human

TIGIT

>1mg/ml

Human IgG4 - kappa

CHO Cells

Anti-Human TIGIT (4E1.2) In Vivo Antibody - Low Endotoxin (ICH1219), Anti-Mouse TIGIT (1G9) In Vivo Antibody - Low Endotoxin (ICH1220), Tiragolumab Biosimilar - Research Grade (ICH5078), Vibostolimab Biosimilar - Research Grade (ICH5159), Belrestotug Biosimilar - Research Grade (ICH5384), Dargistotug Biosimilar - Research Grade (ICH5465), Domvanalimab Biosimilar - Research Grade (ICH5486), Etigilimab Biosimilar - Research Grade (ICH5536), Lancastotug Biosimilar - Research Grade (ICH5623), Ociperlimab Biosimilar - Research Grade (ICH5722), Ralzapastotug Biosimilar - Research Grade (ICH5803), Renvistobart Biosimilar - Research Grade (ICH5816)

https://www.imgt.org/mAb-DB/

ICH3002

Q495A1

Blue ice

Tamgiblimab Biosimilar (Research Grade) is an unconjugated, non-therapeutic research analog of the anti-TIGIT antibody tamgiblimab (originator code IBI939, Innovent Biologics), a fully human IgG4-kappa monoclonal originally developed as a checkpoint immunotherapy for solid tumors, typically explored in combination with PD-1/PD-L1 blockade. This product is built to recapitulate the binding characteristics of the originator against its target, human TIGIT (T-cell immunoreceptor with immunoglobulin and ITIM domains), and is supplied strictly for research use only. It is not a clinical drug and is not intended for therapeutic, diagnostic, or human use. Matching the originator, it carries a human IgG4-kappa framework, which limits Fc effector engagement relative to IgG1-based checkpoint agents. The biosimilar is intended as a consistent, well-characterized reagent for studies of TIGIT biology, ligand-blockade, and checkpoint-pathway crosstalk, and as a reference or control antibody in assay development. As a human-targeted molecule, it is most suited to in-vitro and functional work rather than mouse in-vivo dosing. Available in bulk quantities with low endotoxin research-grade specifications. TIGIT is an inhibitory immune checkpoint receptor expressed on activated T cells, regulatory T cells (Tregs), and natural killer (NK) cells. It binds the ligands CD155 (PVR) and CD112 (PVRL2/nectin-2), which are frequently overexpressed on tumor cells and antigen-presenting cells. Engagement of TIGIT delivers inhibitory signals that dampen T-cell and NK-cell activation and promote functional exhaustion of tumor-infiltrating lymphocytes. TIGIT also competes with the co-stimulatory receptor CD226 (DNAM-1) for the same ligands, further tilting the balance toward immunosuppression, and it can enhance Treg suppressive activity. Because CD155 is upregulated in many malignancies, the TIGIT axis is a prominent target in cancer immunotherapy, often pursued alongside PD-1/PD-L1 blockade. Antibodies that block TIGIT-ligand interactions aim to restore cytotoxic T-cell and NK-cell function within the tumor microenvironment.

V-set and immunoglobulin domain-containing protein 9, V-set and transmembrane domain-containing protein 3, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3

Detects human TIGIT

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks